Seema Kalra
A5102841985- Multiple Sclerosis Research Studies
- T-cell and B-cell Immunology
- Ocular Diseases and Behçet’s Syndrome
- Systemic Lupus Erythematosus Research
- Systemic Sclerosis and Related Diseases
- Cytokine Signaling Pathways and Interactions
- Viral Infections and Immunology Research
- Autoimmune Neurological Disorders and Treatments
- Neurogenesis and neuroplasticity mechanisms
- Peripheral Neuropathies and Disorders
- Psoriasis: Treatment and Pathogenesis
- Neuroinflammation and Neurodegeneration Mechanisms
- Powdery Mildew Fungal Diseases
- Acute Lymphoblastic Leukemia research
- Long-Term Effects of COVID-19
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Immunotherapy and Immune Responses
- Retinal and Optic Conditions
- Health Systems, Economic Evaluations, Quality of Life
- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Diverse Scientific Research Studies
- Epilepsy research and treatment
- vaccines and immunoinformatics approaches
University Hospitals of North Midlands NHS Trust
2017-2025
Keele University
2011-2024
University College London
2024
Universitat Oberta de Catalunya
2024
Fundació Clínic per a la Recerca Biomèdica
2024
UCL Biomedical Research Centre
2024
University of Amsterdam
2024
Monash University
2024
Monash Health
2024
University of Siena
2024
We analyzed genetic data of 47,429 multiple sclerosis (MS) and 68,374 control subjects established a reference map the architecture MS that includes 200 autosomal susceptibility variants outside major histocompatibility complex (MHC), one chromosome X variant, 32 within extended MHC. used an ensemble methods to prioritize 551 putative genes implicate innate adaptive pathways distributed across cellular components immune system. Using expression profiles from purified human microglia, we...
Multiple sclerosis is a complex neurological disease, with ∼20% of risk heritability attributable to common genetic variants, including >230 identified by genome-wide association studies. strands evidence suggest that much the remaining also due additive effects variants rather than epistasis between these or mutations exclusive individual families. Here, we show in 68,379 cases and controls up 5% this explained low-frequency variation gene coding sequence. We identify four novel genes...
BackgroundNeurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test efficacy these an efficient manner with respect time, cost, patient resource.MethodsWe did a phase 2b, multiarm, parallel group, double-blind, randomised placebo-controlled trial at 13 neuroscience centres UK....
Abstract: We assembled and analyzed genetic data of 47,351 multiple sclerosis (MS) subjects 68,284 control establish a reference map the architecture MS that includes 200 autosomal susceptibility variants outside major histocompatibility complex (MHC), one chromosome X variant, 32 independent associations within extended MHC. used an ensemble methods to prioritize up 551 potentially associated genes, implicate innate adaptive pathways distributed across cellular components immune system....
Considerable attention has been given to CCR6+ IL-17-secreting CD4+ T cells (Th17) in the pathology of a number autoimmune diseases including multiple sclerosis (MS). However, other Th subsets also play important pathogenic roles, those that secrete IFNγ and GM-CSF. CCR6 expression by Th17 allows their migration across choroid plexus into cerebrospinal fluid (CSF), where they are involved early phase experimental encephalomyelitis (EAE), MS these elevated CSF during relapses contain high...
Background The prevalence of depression in Multiple Sclerosis (MS) is often assessed by administering patient reported outcome measures (PROMs) examining depressive symptomatology to population cohorts; a recent review summarised 12 such studies, eight which used the Hospital Anxiety and Depression Scale-Depression (HADS-D). In clinical practice, diagnosed an individual structured interview; diagnosis leads treatment options including antidepressant medication. It follows that MS will...
Treatment persistence is the continuation of therapy over time. It reflects a combination treatment efficacy and tolerability. We aimed to describe real-world rates on disease-modifying therapies (DMTs) for people with multiple sclerosis (pwMS) reasons DMT discontinuation.
Recent sero-epidemiological studies have strengthened the hypothesis that Epstein-Barr virus (EBV) may be a causal factor in multiple sclerosis (MS). Given complexity of EBV-host interaction, various mechanisms responsible for disease pathogenesis. Furthermore, it remains unclear whether this is disease-specific process. Here, we showed genes encoding EBV interactors are enriched loci associated with MS but not other diseases and prioritized therapeutic targets. Analyses blood brain...
Reliable measurement of disability in multiple sclerosis (MS) using a comprehensive, patient self-reported scale, such as the World Health Organization Disability Assessment Schedule (WHODAS) 2.0, would be clinical and research benefit.
The nature and extent of inflammation seen in multiple sclerosis (MS) varies throughout the course disease. Changes CD4+ T-helper cells relapsing-remitting (RR) MS secondary progressive (SP) might differ qualitatively and/or quantitatively.The objective this paper is to study frequencies all major subtypes - Th17, Th22 Th1 lineage relapse, remission progression alongside CCR6 status, a chemokine receptor involved migration these into central nervous system.We compared 100 patients (50 RRMS...
Background: The MSIS-29 measures the physical and psychological impact of MS. Objective: associations between domains demographic/clinical aspects were examined trajectories analysed over time. Methods: Data collected in Trajectories Outcome Neurological Conditions study for a diverse population people with MS, follow-up up to 5 years. Following Rasch analysis, minimal important change (MIC) was computed ensuing total, domains. Results: Fit model using data from 5921 participants validated...
Background : The treatment landscape for relapsing multiple sclerosis (MS) has changed dramatically in recent decades, including an increasing number of high-efficacy disease-modifying therapies (DMTs) with varied administration and monitoring requirements. Coupled greater focus on earlier treatment, these factors have resulted stretching the capacity MS specialist services allied healthcare professionals (HCPs). To assist effective planning UK NHS, this study quantified time burden...
Introduction There remains a high unmet need for disease-modifying therapies that can impact disability progression in secondary progressive multiple sclerosis (SPMS). Following positive results of the phase 2 MS-STAT study, MS-STAT2 3 trial will evaluate efficacy and cost-effectiveness repurposed high-dose simvastatin slowing SPMS. Methods analysis be multicentre, randomised, placebo-controlled, double-blind participants aged between 25 65 (inclusive) who have SPMS with an Expanded...
The role of CSF lymphocytic pleocytosis in predicting the clinical outcome multiple sclerosis is unclear. We explored impact at diagnosis on long-term disease progression a large UK cohort.We extracted demographic, and data people with MS attending clinics between 1996 2014 two centres from English Midlands. compared EDSS onset, follow up indices Multiple Sclerosis Severity Score (MSSS), annualized change transition to secondary presence/absence pleocytosis. Two-tailed student t-test,...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is a major challenge for clinicians. SARS-CoV-2 infection results in disease 2019 (COVID-19), and it best known its symptoms. It can also result several extrapulmonary manifestations such as neurological complications potentially experienced during the course of COVID-19. association dermatomyositis (DM) with COVID-19 pathogenesis has not been well-studied. This study aimed to present previously healthy 37-year-old...
Abstract Multiple sclerosis is a common, complex neurological disease, where almost 20% of risk heritability can be attributed to common genetic variants, including >230 identified by genome-wide association studies (Patsopoulos et al., 2017). strands evidence suggest that the majority remaining also due additive effects individual rather than epistatic interactions between these or mutations exclusive families. Here, we show in 68,379 cases and controls as much 5% this explained...